• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Telomir Pharmaceuticals Inc.

    9/18/25 6:48:08 PM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TELO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Telomir Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, no par value

    (Title of Class of Securities)


    87975F104

    (CUSIP Number)


    09/09/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    87975F104


    1Names of Reporting Persons

    John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,774,900.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,774,900.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,774,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.50 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Telomir Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    100 SE 2nd Street Suite 2000 #1009 Miami, FL, 33131
    Item 2. 
    (a)Name of person filing:

    John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
    (b)Address or principal business office or, if none, residence:

    The business address of Mr. DeJoria is 109 West 7th Street, Suite 200, Georgetown, Texas 78626
    (c)Citizenship:

    United States
    (d)Title of class of securities:

    Common Stock, no par value
    (e)CUSIP No.:

    87975F104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,774,900
    (b)Percent of class:

    5.50%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,774,900

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1,774,900

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
     
    Signature:/s/ Matthew R. Bair
    Name/Title:Matthew R. Bair, Attorney-in-Fact
    Date:09/18/2025
    Exhibit Information

    EXHIBIT 24.1 Power of Attorney for John Paul DeJoria

    Get the next $TELO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TELO

    DatePrice TargetRatingAnalyst
    2/21/2025$15.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TELO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Telomir Pharmaceuticals Inc.

    SCHEDULE 13G - Telomir Pharmaceuticals, Inc. (0001971532) (Subject)

    9/18/25 6:48:08 PM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

    9/18/25 7:30:40 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

    8-K - Telomir Pharmaceuticals, Inc. (0001971532) (Filer)

    9/9/25 7:30:50 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TELO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

    MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.The study was conducted in nematodes (C. elegans) with a mutation in the wrn-1 gene, which is equivalent to a gene in humans associated with Werner Syndrome (a form of P

    1/7/25 8:00:00 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

    MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical needs while continuing to explore transformative therapies.Key FindingsRecent preclinical in vitro studies conducted by Recipharm and Smart Assays have demonstrated Telomir-1's exceptional binding affinity for copper io

    12/23/24 7:30:00 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

    Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. The investment, structured as a straightforward common stock transaction, was made at $7 per share representing a 20% premium to the closing price on the date of execution and included no warrants. The restricted shares further emphasize The Starwood Trust's confidence in the company's lon

    12/12/24 8:30:00 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TELO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Telomir Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Telomir Pharmaceuticals with a rating of Buy and set a new price target of $15.00

    2/21/25 8:16:21 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TELO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Weichselbaum Alan

    3 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)

    6/10/25 7:12:56 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and Chairman Aminov Erez

    4 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)

    5/30/25 8:00:11 PM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aminov Erez decreased direct ownership by 0.67% to 29,600 units (SEC Form 5)

    5 - Telomir Pharmaceuticals, Inc. (0001971532) (Issuer)

    2/4/25 4:05:32 PM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TELO
    Leadership Updates

    Live Leadership Updates

    View All

    Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

    MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.Telomir is presently optimizing drug production and forming strategic partnersh

    9/4/24 7:30:00 AM ET
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

    Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 to promote longevity in humans and dogs through the treatment of age-related conditions, today announced the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Out of respect and privacy for Dr. Chapman's family, details of his passing will not be made available. Telomir's Boar

    8/12/24 8:30:00 AM ET
    $MIRA
    $TELO
    Biotechnology: Pharmaceutical Preparations
    Health Care